Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used in the management of type 2 diabetes mellitus. It works by increasing incretin hormone levels, which increase insulin synthesis and decrease glucagon secretion in a glucose-dependent manner. Unlike other DPP-4 inhibitors, linagliptin is primarily excreted via the non-renal route (biliary/fecal).
## Primary Indications
* Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
## Adult Dosing
* **Standard Dose:** 5 mg orally once daily.
* **Maximum Dose:** 5 mg daily.
## Pediatric Dosing
* **Safety and Efficacy:** Not established in pediatric patients (<18 years). Use is not recommended.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment required.
* **Hepatic Impairment:** No dose adjustment required.
## Contraindications
* Hypersensitivity to linagliptin or any component of the formulation.
* History of angioedema or anaphylaxis related to DPP-4 inhibitors.
* Not for treatment of type 1 diabetes or diabetic ketoacidosis.
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with insulin or sulfonylureas).
* **Serious:** Acute pancreatitis (discontinue if suspected), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions (anaphylaxis, angioedema, urticaria).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** Decreased efficacy of linagliptin. Avoid co-administration if possible; monitor glycemic control closely.
* **Insulin/Secretagogues:** Increased risk of hypoglycemia; consider dose reduction of the secretagogue or insulin.
## Monitoring
* **HbA1c:** Typically every 3–6 months.
* **Blood Glucose:** Periodic self-monitoring.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain.
* **Skin:** Observe for blistering or erosions suggestive of bullous pemphigoid.
* **Joint Pain:** Monitor for severe, disabling joint pain.
## Clinical Pearls
* **Unique Excretion:** Linagliptin is the only DPP-4 inhibitor that does not primarily rely on renal clearance, offering a clinical advantage in patients with severe chronic kidney disease.
* **Administration:** It may be taken with or without food.
* **Weight:** Considered weight-neutral.
* **Heart Failure:** Unlike saxagliptin and alogliptin, there is currently no FDA-mandated warning for increased risk of heart failure hospitalization with linagliptin.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Clinical protocols vary by institution. Always verify dosages, contraindications, and drug interactions using current, peer-reviewed resources such as the package insert or clinical decision support tools (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
